Efalizumab
Efalizumab
复制标题
DOI：
10.1111/j.1529-8019.2007.00139.x
复制
发表时间：
2007-07-01
影响因子：
3.6
通讯作者：
Weinberg, Jeffrey M.
中科院分区：
文献类型：
--
作者：
Chacko, Manju;Weinberg, Jeffrey M.
Efalizumab 是一种新型免疫调节剂，可阻止 T 细胞迁移和激活。该药物最初于 2003 年 10 月被批准用于治疗慢性中度至重度斑块状银屑病成年患者。本综述将讨论 efalizumab 治疗银屑病的疗效和安全性数据。在临床应用中，efalizumab 可作为斑块型银屑病的一线生物疗法，也是手足银屑病、超重患者和对 TNF 抑制剂反应不足的患者的一线选择。此外，还将审查 efalizumab 的几种超说明书应用。
Efalizumab is a novel immunomodulator that blocks T-cell migration and activation. The drug was initially approved in October 2003 for the treatment of adult patients with chronic moderate to severe plaque psoriasis. This review will discuss the efficacy and safety data for efalizumab in the treatment of psoriasis. In clinical use, efalizumab has utility as a first-line biologic therapy for plaque psoriasis, as well as a first-line choice for hand and foot psoriasis, overweight patients, and those who have had inadequate response to a TNF inhibitor. In addition, several off-label applications of efalizumab will be reviewed.